Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; lactose monohydrate; microcrystalline cellulose; magnesium stearate; iron oxide red; silicon dioxide; sodium starch glycollate type a; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 100 mg - capsule, hard - excipient ingredients: iron oxide red; silicon dioxide; lactose monohydrate; iron oxide yellow; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 125 mg - capsule, hard - excipient ingredients: silicon dioxide; sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; iron oxide red; lactose monohydrate; titanium dioxide; iron oxide yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - palbociclib -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - palbociclib -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - palbociclib -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide red; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide red; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - palbociclib, quantity: 100 mg - capsule, hard - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - cip palbociclib is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy